Cure of xenografted human carcinomas by BR96-doxorubricin immunoconjugates

Immunoconjugates (BR96-DOX) were prepared between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin. The monocional antibody binds an antigen related to Lewis Y that is abundantly expressed at the surface of cells from many human carcinomas; it has a high degree of tumor selectiv...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 1993-07, Vol.261 (5118), p.212
Main Authors: Trail, P.A, Willner, D, Lasch, S.J, Henderson, A.J, Hofstead, S, Casazza, A.M, Firestone, R.A, Hellstrom, I, Hellstron, K.E
Format: Article
Language:English
Subjects:
Antibody-toxin conjugates
Cancer
Chemotherapy
Doxorubicin
Health aspects
Immunotoxins
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunoconjugates (BR96-DOX) were prepared between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin. The monocional antibody binds an antigen related to Lewis Y that is abundantly expressed at the surface of cells from many human carcinomas; it has a high degree of tumor selectivity and is internalized after binding. BR96-DOX induced complete regressions and cures of xenografted human lung, breast, and colon carcinomas growing subcutaneously in athymic mice and cured 70 percent of mice bearing extensive metastases of a human lung carcinoma. Also, BR96-DOX cured 94 percent of athymic rats with subcutaneous human lung carcinoma, even though the rats, like humans and in contrast to mice, expressed the BR96 target antigen in normal tissues.
ISSN:0036-8075
1095-9203